Brief Title
Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy
Official Title
Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy
Brief Summary
The aim of this study is to detect effect of allopurinol supplementation in pediatric
patients with dilated cardiomyopathy.
Detailed Description
DCM as a serious cardiac disorder in which structural or functional abnormalities of the
heart muscle can lead to substantial morbidity and mortality owing to complications such as
heart failure and arrhythmia Among patients with heart failure (HF), elevated serum uric acid
levels and increased oxidative stress have been associated with increased mortality,
implicating xanthine oxidase as a possible therapeutic target Xanthine oxidase (XO), a
superoxide-generating enzyme, is up regulated in animals (6,7) and in humans with heart
failure. Acute administration of the XO inhibitor allopurinol improves the mechanical
efficiency of the failing heart ), whereas oxygen consumption paradoxically decreases. Direct
XO inhibition in cardiac muscle leads to increased force generation by the myofilaments at
any given level of activator calcium(10).
Allopurinol, an inhibitor of xanthine oxidase, may be a novel therapeutic agent for HF.
Allopurinol reduces uric acid levels, prevents acute gout, and acts as an anti oxidant, which
could be beneficial among HF patients(5)
Study Type
Observational
Primary Outcome
difference of echocardiography parameters and ejection fraction between DCM patients taking Allopurinol and patients not taking
Condition
Dilated Cardiomyopathy
Intervention
Allopurinol Tablet
Study Arms / Comparison Groups
Allopurinol
Description: we plan to follow up effect of Allopurinol on left ventricular function in children with dilated cardiomyopathy for 6 months
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
100
Start Date
May 1, 2022
Completion Date
July 2023
Primary Completion Date
May 2023
Eligibility Criteria
Inclusion Criteria:
1 - children (1-16) year's age with impaired left ventricular systolic function due to
dilated cardiomyopathy, who attend pediatric cardiology unit 2-children attend to pediatric
cardiology out patient clinic in Assiut university children hospital 3-children with no
allergic reaction from allopurinol
Exclusion Criteria:
1. children with impaired left ventricular systolic function due to other causes like
congenital heart diseases
2. children with acquired heart diseases
3. patients with allergic reaction or contra indicated from Allopurinol
Gender
All
Ages
1 Year - 16 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, 01030709367, [email protected]
Administrative Informations
NCT ID
NCT05193838
Organization ID
Allopurinol
Responsible Party
Principal Investigator
Study Sponsor
Assiut University
Study Sponsor
, ,
Verification Date
January 2022